Wednesday, November 11, 2020 2:49:54 PM
The cart was before the horse before. They truly have great IP just a really incompetent CEO. I truly believe that in the end the science wins out over their incompetence just like it did with Medistem. They are doing all of the hard work now to make it turnkey because they know running daily operations and executing business plans is not what they do. IP + Development IP + Commercialization = $. Lots of biotechs out there and I haven't come across any that have this much workable IP. Despite of themselves and their incompetence this is still a long hold.
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:45:54 PM
- Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies • GlobeNewswire Inc. • 04/28/2026 01:01:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:45:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 08:45:28 PM
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline • GlobeNewswire Inc. • 02/10/2026 02:00:00 PM
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain • GlobeNewswire Inc. • 01/13/2026 02:15:00 PM
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative • GlobeNewswire Inc. • 01/06/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:58 PM
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point • GlobeNewswire Inc. • 12/17/2025 02:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/16/2025 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2025 05:15:26 AM
- Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 • GlobeNewswire Inc. • 12/02/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2025 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 11:12:58 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:46:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:42 PM
- Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits • GlobeNewswire Inc. • 10/30/2025 01:15:00 PM
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds • GlobeNewswire Inc. • 10/29/2025 01:00:00 PM
- Creative Medical Technology Holdings Issues Letter to Shareholders • GlobeNewswire Inc. • 10/27/2025 12:15:00 PM
- Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs • GlobeNewswire Inc. • 10/07/2025 01:15:00 PM
